Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease-Reference-Cited by-同舟云学术

Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease

Published:2020-06-02 Issue:2 Volume:374 Page:342-353
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

del Balzo Ughetta^ORCID,Signore Pierre E.,Walkinshaw Gail,Seeley Todd W.,Brenner Mitchell C.,Wang Qingjian,Guo Guangjie,Arend Michael P.,Flippin Lee A.,Chow F. Aisha,Gervasi David C.,Kjaergaard Christian H.,Langsetmo Ingrid,Guenzler Volkmar,Liu David Y.,Klaus Steve J.,Lin Al,Neff Thomas B.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference66 articles.

1. Hyporesponsiveness to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: The Many Faces of Inflammation

2. Intestinal Hypoxia-inducible Factor-2α (HIF-2α) Is Critical for Efficient Erythropoiesis

3. Mechanisms of Anemia in CKD

4. Pharmacological Characterization of 1-(5-Chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic Acid (JNJ-42041935), a Potent and Selective Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

5. Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypoxia inducible factor 2α promotes tolerogenic macrophage development during cardiac transplantation through transcriptional regulation of colony stimulating factor 1 receptor;Proceedings of the National Academy of Sciences;2024-06-18

2. A preliminary study of roxadustat in the treatment of aplastic anemia patients with inadequate erythroid responses;Annals of Hematology;2024-05-22

3. Consensus commentary and position of the Italian Society of Nephrology on KDIGO controversies conference on novel anemia therapies in chronic kidney disease;Journal of Nephrology;2024-05-06

4. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association;Nephrology Dialysis Transplantation;2024-04-04

5. Impact of C-reactive protein on the effect of Roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials;BMC Nephrology;2024-02-05